Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease (IBD) at Weill Cornell Medicine, is the lead investigator on a grant to Weill Cornell Medicine from The Leona M. and Harry B. Helmsley Charitable Trust to target pathogenic fungi in patients with Crohn’s disease. Dr. Iliev teamed up with Dr. Randy Longman, current director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell…
Author: Abhay Panchal
ActionFDA has approved Linzess (linaclotide) capsules to treat functional constipation in pediatric patients 6 to 17 years of age. Linzess is the first treatment for pediatric functional constipation. The recommended dosage in pediatric patients 6 to 17 years is 72 mcg orally once daily. Disease or ConditionFunctional constipation is a common condition experienced by children and adolescents in which patients have infrequent bowel movements with hard stools that can be difficult or painful to pass. There is no known underlying organic cause and there are typically multiple contributing factors.
Medscape on June 9 released its “Physician Wealth and Debt Report 2023,” which polled physicians on compensation, debt and expenses. The report surveyed 10,011 physicians across more than 29 specialties about their income, net worth, and more from Oct. 7 to Jan. 17. Here are the expenses and debts physicians reported paying down:
The article discusses the recent Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Merck’s experimental drug, efinopegdutide, for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a progressive form of fatty liver disease with no approved medications currently available. The Fast Track designation signifies the FDA’s recognition of the drug’s potential to address an unmet medical need in a serious condition. It expedites the development and review process, allowing for more frequent communication between Merck and the FDA to accelerate the drug’s evaluation.
The article presents various real-life scenarios that doctors encounter, such as the decision to withhold or withdraw life-sustaining treatment, dealing with patients who refuse life-saving interventions due to personal beliefs, and grappling with the consequences of medical errors. These ethical challenges often leave physicians torn between their duty to heal and respecting patient autonomy. The personal accounts of physicians reveal the deep emotional impact and moral distress caused by these dilemmas. Feelings of guilt, burnout, and loss of professional identity are common repercussions, leading some doctors to reconsider their career paths or experience profound emotional exhaustion.
A bill in the Maine legislature would have the medical malpractice statute of limitations clock start running when a patient discovers the negligence, which could be years after treatment took place. And other states could follow suit with similar bills. What danger does this pose for doctors? As it stands, the time limit for patients to be able to bring a medical malpractice lawsuit varies by state. The bill that was introduced in Maine would enable patients to bring suits many years after treatment took place. For physicians, this extends their period of liability and could potentially increase the number…
Here are 10 gastroenterology groups who have grown their footprint so far in 2023:
Four experts share what you need to know about the role of endoscopy in recurrent acute and chronic pancreatitis.
During the esophagus session at the AGA Postgraduate Course 2023, significant updates in esophagology were presented. Key highlights include novel care approaches for esophageal diseases, such as GERD, extraesophageal reflux, and Barrett’s esophagus, based on recent AGA best practice updates. Additionally, randomized clinical trial data examined therapeutic approaches for erosive esophagitis and eosinophilic esophagitis. One notable finding was the effectiveness of potassium competitive acid blockers, which demonstrated faster and stronger suppression of gastric acid secretion compared to traditional PPI therapy for healing erosive esophagitis, a critical step in preventing further complications.
Google Cloud and Mayo Clinic have announced a groundbreaking partnership to harness generative AI and Enterprise Search for healthcare improvement. Mayo clinicians and researchers will gain access to Google’s HIPAA-compliant tools, enabling more efficient data navigation and curated search results. This collaboration holds great potential for revolutionizing healthcare by providing quick access to complex data sets, enhancing treatment strategies, and empowering clinicians with advanced search capabilities.